Catalyst Pharmaceuticals (CPRX) Expected to Announce Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) is expected to announce its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Catalyst Pharmaceuticals to post earnings of $0.42 per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $24.64 on Wednesday. Catalyst Pharmaceuticals has a fifty-two week low of $19.05 and a fifty-two week high of $26.58. The firm has a market cap of $3.03 billion, a P/E ratio of 14.33, a P/E/G ratio of 0.81 and a beta of 0.74. The business’s 50 day moving average price is $23.76 and its 200-day moving average price is $22.03.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 26,746 shares of Catalyst Pharmaceuticals stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $23.25, for a total value of $621,844.50. Following the completion of the transaction, the director directly owned 2,360 shares of the company’s stock, valued at approximately $54,870. The trade was a 91.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Carmen Jeffrey Del sold 10,983 shares of the business’s stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $23.33, for a total transaction of $256,233.39. Following the completion of the transaction, the insider owned 3,962 shares of the company’s stock, valued at approximately $92,433.46. The trade was a 73.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 10.40% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Deerfield Management Company L.P. boosted its stake in shares of Catalyst Pharmaceuticals by 72.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after buying an additional 2,095,291 shares during the last quarter. Morgan Stanley lifted its stake in shares of Catalyst Pharmaceuticals by 59.1% during the 4th quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock valued at $68,466,000 after buying an additional 1,089,775 shares in the last quarter. Glenmede Investment Management LP boosted its stake in shares of Catalyst Pharmaceuticals by 781.8% in the third quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock worth $13,400,000 after acquiring an additional 603,084 shares during the period. Bank of America Corp DE grew its position in shares of Catalyst Pharmaceuticals by 30.6% during the second quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock worth $51,335,000 after purchasing an additional 554,200 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Catalyst Pharmaceuticals by 28.9% during the third quarter. Dimensional Fund Advisors LP now owns 2,458,169 shares of the biopharmaceutical company’s stock worth $48,424,000 after purchasing an additional 550,648 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Analysts Set New Price Targets

CPRX has been the topic of several recent analyst reports. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Monday, December 29th. Citigroup lifted their target price on shares of Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th. Finally, Oppenheimer restated an “outperform” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $33.20.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).